1991
DOI: 10.1093/clinids/13.4.653
|View full text |Cite
|
Sign up to set email alerts
|

Aspergillosis of the CNS in a Pediatric Liver Transplant Recipient: Case Report and Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
19
0
5

Year Published

1992
1992
2014
2014

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 54 publications
(24 citation statements)
references
References 43 publications
0
19
0
5
Order By: Relevance
“…Craniotomy with excision and/or drainage [22][23][24][25][26] for diagnostic and therapeutic purposes should play an active role in the treatment of these patients. The role of newer antifungal agents, such as liposomal amphotericin B or itraconazole, is still unclear.…”
Section: Fungal Brain Abscessesmentioning
confidence: 99%
“…Craniotomy with excision and/or drainage [22][23][24][25][26] for diagnostic and therapeutic purposes should play an active role in the treatment of these patients. The role of newer antifungal agents, such as liposomal amphotericin B or itraconazole, is still unclear.…”
Section: Fungal Brain Abscessesmentioning
confidence: 99%
“…About 14 cases of intracranial aspergillosis in infants have been reported till recently[891011] among them only 2 had multiple brain abscess. Four of the 14 cases were operated of whom only 3 survived.…”
Section: Discussionmentioning
confidence: 99%
“…35 Children undergoing LTx for cystic fibrosis are at particular risk of developing infection due to aspergillus. 35 A history of recovery of aspergillus prior to transplant should prompt the use of antifungal prophylaxis in liver recipients with cystic fibrosis.…”
Section: Bacterial and Fungal Infectionsmentioning
confidence: 99%
“…35 Children undergoing LTx for cystic fibrosis are at particular risk of developing infection due to aspergillus. 35 A history of recovery of aspergillus prior to transplant should prompt the use of antifungal prophylaxis in liver recipients with cystic fibrosis. Data defining the precise duration of prophylaxis are not available, and prophylactic treatment has ranged from 1 month of intravenous amphotericin to prolonged use of an oral azole agent (ie, voriconazole).…”
Section: Bacterial and Fungal Infectionsmentioning
confidence: 99%